37 results about "Digoxin" patented technology

The invention discloses a preparation method of minoxidil liniment. The preparation method comprises the following steps: uniformly mixing propylene glycol, absolute ethyl alcohol and about 40% purified water until no obvious layering exists, and finally adding minoxidil to stir and dissolve to obtain the minoxidil liniment. According to the preparation process provided by the invention, purified water and absolute ethyl alcohol can form a latent solvent, so that the solubility of minoxidil in a single auxiliary material is greatly improved, and subsequent preparation of the digoxin injection is facilitated.

The invention relates to the technical field of biological products, and discloses a mesenchymal stem cell hair growth liquid and a preparation method thereof, and the mesenchymal stem cell hair growth liquid comprises the following components: hair follicle mesenchymal stem cells; a hair follicle mesenchymal stem cell exosome; growth factors: a vascular endothelial growth factor (VEGF), a fibroblast growth factor (FGFs), a keratinocyte growth factor (KGF-7) and interleukin-10 (IL-10); vitamins: vitamin E, vitamin B5, vitamin B2, vitamin B6, vitamin C and biotin; the plant extracts comprise a cacumen biotae extract, a polygonum multiflorum extract, a ginseng extract, a peppermint extract, a purslane extract and a rhodiola rosea extract; other active ingredients: tripeptide and digoxin; the auxiliary material is a hyaluronic acid-collagen peptide graft copolymer; and the balance of a phosphate buffer solution.

The application provides an anti-digoxin antibody or antigen binding fragment thereof and application thereof, and relates to the technical field of antibodies. The anti-digoxin antibody or antigen binding fragment thereof comprises a heavy chain variable region and a light chain variable region; the heavy chain variable region comprises VHCDR1 of the 17th-24th amino acid residues at the N terminus of the amino acid sequence shown in SEQ ID NO. 1, VHCDR2 of the 42nd-49th amino acid residues, and VHCDR3 of the 88th-98th amino acid residues; and the light chain variable region comprises VLCDR1 of the 27th-37th amino acid residues at the N terminus of the amino acid sequence shown in SEQ ID NO. 2, VLCDR2 of the 55th-57th amino acid residues, and VLCDR3 of the 94th-102th amino acid residues. The antibody or antigen binding fragment thereof can be used for immunological detection, and has been verified to have good specific binding capacity.

The application provides a quantum dot microsphere fluorescent immunochromatography test paper for combined detection of ASFV antibodies and nucleic acids and an application thereof, and belongs to the technical field of veterinary biological diagnosis products. The quantum dot microsphere fluorescent immunochromatography test paper for combined detection of ASFV antibodies and nucleic acids comprises a base plate, on the base plate, a sample pad, a combination pad, a nitrocellulose membrane and a water absorption pad are sequentially connected in a head-to-tail mode, from the combination pad to the water absorption pad, the nitrocellulose membrane is sequentially provided with an antibody detection line, a nucleic acid detection line and a quality control line, the antibody detection line is coated with a goat anti-pig IgG-Fc antibody, the nucleic acid detection line is coated with streptavidin, and the quality control line is coated with a rabbit anti-sheep IgG antibody; the combination pad is coated with a quantum dot microsphere labeled recombinant protein P22 and a quantum dot microsphere labeled sheep anti-digoxin antibody. The test paper can rapidly, highly specifically and highly sensitively detect ASFV antibodies and nucleic acids.

The invention discloses a digoxin drug concentration detection method, which comprises: S1, determining a to-be-detected drug, and carrying out working curve preparation on a detection object, the to-be-detected drug being digoxin; s2, taking out the to-be-detected sample, the calibration product, the quality control product and the internal standard extraction liquid, placing at room temperature, and uniformly mixing; s3, respectively taking a to-be-detected sample, a calibration product, a quality control product and a blank sample, putting into an EP tube, adding the internal standard intermediate solution, adding methanol, uniformly mixing by vortex, and centrifuging; s4, putting the supernate into a 96-well plate, adding ultrapure water, and putting the 96-well plate on a microwell plate oscillator for shaking; and S5, centrifuging in a multi-tube rack automatic balancing centrifuge, detecting and verifying by using liquid chromatogram-tandem mass spectrum, and collecting a mass spectrum signal. According to the present invention, the high performance liquid chromatography separation and the mass spectrometry are combined, such that the complex background interference in the blood sample is overcome, the cost performance is improved, and the high sensitivity, the high accuracy and the convenient detection can be achieved for the digoxin sample with the low in-vivo concentration.

The present invention relates to digoxin injection and a preparation method thereof. The digoxin injection is preferably in the specification of 2ml:0.5mg. The digoxin injection of the present invention has a small amount of alcohol auxiliary materials and good stability, which is significantly better than the prior art and can improve the safety of medication and the convenience of production.

This application relates to the technical field of biomarkers, and particularly to a preparation method and application of an RNA vector-related translocation complex; the translocation complex includes an RNA vector, and the RNA vector includes an RNA vector core sequence, a biotin-labeled primer, and a digoxigenin-labeled primer. The forward sequence of the RNA vector core sequence is shown in SEQ ID NO.1, and the reverse sequence of the RNA vector core sequence is shown in SEQ ID NO.2; through the RNA vector including the RNA vector core sequence, the biotin-labeled primer, and the digoxigenin-labeled primer, one end of the RNA vector is connected to streptomycin-coated magnetic beads through the biotin-labeled primer, and the other end is connected to the digoxigenin-treated glass surface, with firm binding. The RNA vector core region can form a translocation complex with the Holo-RdRp polymerase and the nsp13 helicase, and the single-molecule magnetic tweezer technology can effectively reflect the kinetic characteristics of the nsp13 reaction in real time.

The present invention relates to the field of pharmaceutical technology, and specifically to the application of a macrolide derivative in the preparation of a drug for treating heart failure. The present invention provides a new use of a macrolide derivative. Experimental results show that this macrolide derivative significantly improves the cardiac function of heart failure mice, increases the ejection fraction (EF%), fractional shortening (FS%), and cardiac output per minute (CO), without changing the heart rate (HR), is equivalent to the positive drug digoxin, and is superior to enalapril; at the same time, it has the effects of reducing the heart weight ratio, improving myocardial hypertrophy and fibrosis, and has good clinical prospects and social benefits.

The invention provides a dilated cardiomyopathy child death risk prediction method, system and device, and relates to the technical field of medical prediction models.The method comprises the steps that clinical data of a target dilated cardiomyopathy child patient are obtained and input into a pre-constructed nomogram prediction model, and death risk prediction results of the target dilated cardiomyopathy child patient at multiple time points in the future are output; the nomogram prediction model is constructed through independent prediction factors, the amino-terminal brain natriuretic peptide precursor level, the gender and the digoxin use condition which are determined through single-factor and multi-factor Cox regression analysis. According to the method, the nomogram prediction model is constructed by integrating the key clinical variables, accurate prediction and individualized treatment guidance of the dilated cardiomyopathy death risk of children are achieved, and the accuracy of clinical decision and the prognosis management effect are effectively improved.

The invention belongs to the technical field of molecular biology, and particularly relates to a base calibration reagent for next-generation sequencing, a kit and application of the base calibration reagent. The base calibration reagent comprises streptavidin modified by fluorophores with different wavelengths and anti-digoxin, and the fluorophores are connected with the streptavidin and the anti-digoxin, so that the number and the variety of the fluorophores can be adjusted to achieve a stronger fluorescence signal and a higher signal-to-noise ratio, and the data quality of DNA sequencing is further improved.

This application relates to a digoxin detection kit. Specifically, the 6-glucose phosphate dehydrogenase mutant of this application comprises one or a combination of the following mutations compared to wild-type 6-glucose phosphate dehydrogenase: D306C, D375C, and G426C. The detection kit prepared using the 6-glucose phosphate dehydrogenase mutant of this application has strong specificity, high sensitivity, convenient operation, short detection time, and accurate quantitative determination, making it suitable for high-throughput detection.

The invention discloses a triple LAMP-LFD (loop-mediated isothermal amplification-lateral flow dipstick) detection kit for simultaneously detecting three bovine diarrhea syndrome viruses and a detection method thereof, and relates to the field of agricultural gene detection.The detection kit comprises a binding pad coated with a colloidal gold solution labeled by an antibiotin monoclonal antibody, a sample pad, an NC (nitrocellulose) membrane, an absorption pad and a quality control line C covered with a goat anti-mouse polyclonal antibody, the kit comprises a detection line T1 covered with an anti-digoxin antibody, a detection line T2 covered with an anti-ROX antibody, a detection line T3 covered with an anti-FAM monoclonal antibody, an LFB detection line, a primer designed aiming at M31182.1, a primer designed aiming at JN191349.1 and a primer designed aiming at JN790188.1; the detection method provided by the invention has the advantages of quick result, high cost benefit and higher accuracy.

At least one pharmaceutical composition for use in a method of prophylaxis or treatment of COVID wherein the at least one pharmaceutical composition comprises donepezil, rivastigmine or galantamine or one of donepezil, rivastigmine or galantamine combined with one of: Artemether and Lumefantrine; Atazanavir Sulfate; Efavirenz; Fosamprenavir Calcium; Saquinavir; Remdesivir (GS-5734); Digoxin; Memantine; Rivastigmine; Galantamine; Valsartan; Teriflunomide and wherein the method of prophylaxis or treatment of COVID or COVID-19 comprises: providing a subject in need of said prophylaxis or treatment; providing the at least one pharmaceutical composition as defined supra; wherein said components are provided together or separately; wherein said components are administered together or separately; and wherein said components are provided in a pharmaceutically acceptable diluent, adjuvant and / or excipient; and administering a pharmaceutically effective amount of said at least one pharmaceutical composition to said subject; and wherein, in the method, said subject is provided prophylaxis or treatment of COVID and COVID relates to a human coronavirus, mouse hepatitis virus (MHV), or recombinant mouse-adapted SARS-CoV (SARS-CoV MAI 5).

The application discloses a digoxin nanobody and a preparation method and application thereof. The amino acid and nucleotide sequences of the digoxin nanobody are shown in SEQ ID NO. 8-9. The antibody has good affinity to a target antigen, and the dissociation constant Kd value is about 73.1 nM, and can be used for digoxin content determination, nucleic acid probe detection and in-vivo digoxin neutralization and detoxification. The antibody has the advantages of small volume, high stability, low cost, low immunogenicity and the like, and has a good application prospect.

The present invention relates to a humanized antibody having excellent binding affinity for digoxigenin and its uses. When using an antibody or an antigen-binding fragment thereof that specifically recognizes digoxigenin according to an embodiment of the present invention, it can be expected to regulate the concentration of a drug in vivo as needed or increase the half-life of the drug in a living body by means of a complex (DOligobody) containing the same.

The invention relates to application of an activating agent in promotion of uranium element discharge. Specifically, the activating agent is prepared from rifampicin, erythromycin, progesterone, aldosterone, bilirubin, cholate vinblastine, doxomicin, adriamycin, paclitaxel, bosentan, ambrisentan, digoxin, verapamil, tonavir, amprenavir, indinavir, hypericum perforatum juice, curcumin, atorvastatin beclomethasone, budesonide, divaricasone carbamazepine and caffeine. And phenytoin. The use dosage of the activating agent is 10 to 60 mg / kg. According to the method, the accumulation amount of uranium in important organs such as bones and kidneys can be remarkably reduced, so that the potential toxic influence on the key organs is reduced.

The invention provides a probe, a freeze-drying reagent, a lateral flow chromatography test strip, a kit and a method for detecting RNase activity, and relates to the technical field of biology. According to the present invention, based on the specific antigen-antibody reaction and the immunochromatography technology, the RNA probe with the 5'end labeled with digoxin and the 3 'end labeled with biotin is selected as the substrate, and under the condition that the sample to be detected contains RNase and is mixed with the substrate, the RNase can specifically recognize and cut the phosphodiester bond on the RNA probe so as to fragment the RNA; then, the test strip is inserted into the reacted reagent, if the sample does not contain RNase, the RNA probe is not subjected to enzyme digestion and can be fixed on the quality control line and combined with streptavidin, the quality control line shows a red strip, and the detection line does not develop color; if RNase exists in the sample, the RNA probe is fixed on the detection line after being subjected to enzyme digestion and is combined with the secondary antibody, and a red strip appears on the detection line.

The invention relates to a digoxin immunodetection reagent as well as a preparation method and a detection method thereof, in particular to a digoxin chemiluminescence immunodetection reagent as well as a preparation method and a detection method thereof, and the digoxin chemiluminescence immunodetection reagent comprises an anti-digoxin specific antibody and an indicating reagent for detecting an anti-digoxin specific antibody-digoxin conjugate, the anti-digoxin specific antibody is obtained by immunizing animals with digoxin immunogen. The digoxin immunogen has the beneficial effects that the digoxin immunogen has strong specificity and high immunogenicity, and the prepared anti-digoxin specific antibody has strong specificity and high titer; the chemiluminescence immunoassay reagent containing the anti-digoxin specific antibody can conveniently, quickly and accurately determine the content of digoxin in a sample, can simultaneously determine a plurality of samples on a full-automatic chemiluminescence immunoassay analyzer, realizes high-flux quick determination of digoxin, and is high in accuracy, strong in specificity and high in sensitivity. And the accuracy and the detection efficiency are greatly improved.

The invention discloses a method for detecting digoxin related substances. The method comprises the following steps: using a high performance liquid chromatograph to detect a test solution, adopting a C18 chromatographic column, using acetonitrile as a mobile phase A, using water as a mobile phase B, and performing gradient elution: from 0 to 23 minutes, the mobile phase A is 25%; from 23 to 45 minutes, the mobile phase A is increased from 25% to 40%; from 45 to 55 minutes, the mobile phase A is increased from 40% to 80%; from 55 to 55.5 minutes, the mobile phase A is reduced from 80% to 25%; and then balancing for 60 minutes with the mobile phase A being 25%. The detection method of the invention is used to separate and determine the related substances in digoxin raw materials and preparations, especially digoxin injections. The method has many detectable impurities, good separation between peaks, high sensitivity, good repeatability and recovery rate, and can control 10 key known impurities and 6 unknown impurities, thereby facilitating the quality control of digoxin preparations.

The invention belongs to the technical field of biology, and particularly discloses an anti-digoxin monoclonal antibody and application thereof. A conjugate DIG-BSA of hapten in-situ goxin and BSA is used as an artificial complete antigen to immunize a BALB / c mouse, a hybridoma cell strain DIG-14B4 capable of stably secreting an anti-DIG monoclonal antibody is screened out by utilizing sandwich ELISA, and then the anti-DIG monoclonal antibody with high affinity and high specificity is prepared by adopting an in-vivo ascites inducing method. The anti-DIG monoclonal antibody can be used for immunochromatography detection and can accurately, sensitively, quickly and specifically detect protein or nucleic acid molecules labeled by a DIG probe, so that qualitative and semi-quantitative detection of target protein or nucleic acid molecules is realized.

The invention belongs to the technical field of molecular biology, and discloses a preparation method of a fluorescence in situ hybridization kit based on a hybridization chain reaction (HCR), the core components of the kit comprise a hybridization probe, an amplification probe, a washing liquid, a confining liquid, protease K, HRP-mouse anti-digoxin, and a TSA developing liquid 520 nm. According to the FISH detection system combined with the HCR signal amplification technology, when a hybridization probe and an amplification probe are simultaneously combined to a position adjacent to a target sequence, a small section of sequence at the top end can trigger a branched HCR reaction to form a macromolecular nucleic acid aggregate. Signal amplification of HCR is achieved through cascade hybridization reaction, detection sensitivity and specificity can be remarkably improved, and meanwhile the problem of background noise caused by a traditional enzymatic method is avoided. The kit disclosed by the invention is wide in sample application range, and can be used for positioning analysis of target RNA of samples such as paraformaldehyde or formalin-fixed animal and plant tissues, paraffin or frozen sections, cells and the like, and high-sensitivity detection of the single cell level of non-coding RNA.

This invention belongs to the pharmaceutical field, specifically relating to the application of the combination of digetuxine and Lactobacillus reuteri in the preparation of an anti-amputation carcinoma drug. Through in vitro MTT assays of antitumor activity, this invention found that the combination of the cardiac glycoside drug digetuxine and the probiotic Lactobacillus reuteri can inhibit the proliferation of ampullary cancer cells and has a good inhibitory effect on ampullary carcinoma xenograft models. Furthermore, this combination alleviates the intestinal toxicity of digetuxine, and its therapeutic effect is superior to that of the commonly used clinical drug 5-fluorouracil, showing promising application prospects.

The invention discloses an application of Digoxin in preparation of a medicine for treating and / or preventing tumors. It is found for the first time that Digoxin can enhance the esophageal cancer radiotherapy sensitivity. Digoxin is a medicine which is approved by FDA, small in toxic and side effects and moderate in price, can be prepared into capsules for oral administration, and is used for radiotherapy sensitization of esophageal cancer and inhibition of growth of esophageal cancer.

The invention relates to the technical field of nucleic acid detection, in particular to a detection method and a detection system for detecting serum HBVpg-RNA and application of the detection method and the detection system. The detection system comprises a DNA probe and a lateral flow immunochromatography test strip, the DNA probe comprises a probe H1 and a probe H2, the sequence of the probe H1 is as shown in SEQ ID NO.1, and the 5'end is modified with digoxin; the sequence H2 is as shown in SEQ ID NO.2, and the 5'end is modified with biotin; the lateral flow immunochromatography test strip comprises a sample pad, a combination pad, a nitrocellulose membrane and an absorption pad. According to the detection system provided by the invention, the DNA probe and the target RNA are mixed to catalyze the hairpin self-assembly reaction and are combined with the immunochromatography test strip, so that professional personnel do not need to operate equipment for detection, the operation is simple, the consumed time is short, and the detection cost is obviously reduced.

The application provides a digoxin microtablet and a preparation method thereof. The digoxin microtablet prepared by the application contains 5-100 micrograms of digoxin per tablet, which can meet the dosage requirements of patients of different ages, realize precise dosage administration, and reduce the risk of drug overdose in clinical application. The digoxin microtablet provided by the application can solve the problem that infants and children have difficulty in swallowing the medicine, thereby improving the medication compliance of infants and children. Compared with conventional tablets, the microtablet has a smaller volume. The digoxin microtablet provided by the application is prepared by optimizing the prescription and process, preparing a digoxin compound by a spray drying and hot melt extrusion technology, obtaining a solid dispersion, and having better content uniformity and dissolution rate, and significantly improving the bioavailability.

The invention relates to the field of a preparation method and application of an adriamycin liposome nano-drug, in particular to a preparation method and application of an ionizable adriamycin liposome nano-drug taking digoxin as a fifth component. The protonation effect (piperazine with a tertiary amine structure is protonated to form cations under an acidic condition) of an ionizable lipid delivery carrier under the action of an acidic microenvironment of tumor tissues is utilized to repel protonated DOX, so that the DOX is quickly and efficiently released, and the toxic and side effects of DOX-coated D-LNP are reduced; the medicine DIG with the cardiovascular protection effect is used for reducing the DOX-mediated cardiotoxicity; and meanwhile, the anti-tumor effect of the DOX-coated D-LNP is improved by utilizing the anti-tumor effect of the DIG.

This invention relates to the field of diclofenac preparation technology and discloses a method for preparing high-purity diclofenac, comprising the following steps: synthesis of BOC-D-phenylalanine-D-phenylalanine-D-leucine-N'-BOC-D-lysine; synthesis of BOC-D-phenylalanine-D-phenylalanine-D-leucine-N'-BOC-D-lysine-4-(Trt-amino)piperidine-4-carboxylic acid ethyl ester; synthesis of D-phenylalanine-D-phenylalanine-D-leucine-D-lysine-4-aminopiperidine-4-carboxylic acid ethyl ester; and synthesis of diclofenac. The key intermediates in the synthesis process of this invention can be obtained by precipitation or recrystallization, without the need for purification using chromatography columns or HPLC, offering advantages such as convenient operation and low cost, and ultimately producing high-purity diclofenac.

1. The name of the design product: packaging box (digoxin injection). 2. The use of the design product: the design product is used for packaging medicines. 3. The design points of the design product: the pattern of the product. 4. The picture or photo that best indicates the design points: front view.

The present invention provides a nanoparticle and a preparation method and application thereof, and relates to the technical field of pharmaceutical preparations. The nanoparticle comprises a nano self-assembled particle and a homotypic tumor cell membrane; wherein the nano self-assembled particle is mainly prepared by self-assembly of digoxin and doxorubicin, and the prepared nano self-assembled particle does not need to introduce a carrier material, and can achieve the effect of high drug loading; at the same time, the surface of the nano self-assembled particle of the present application is coated with a homotypic tumor cell membrane, and since the surface of the tumor cell membrane has a variety of antigens, the nanoparticle of the present application has the characteristics of immune escape and homotypic binding with tumor cells, thereby improving its tumor targeting and escaping the host immune system. Therefore, the nanoparticle prepared by the present application has the advantages of high drug loading and strong tumor targeting, and while improving the existing anti-tumor treatment effect, it has stronger targeting and can effectively reduce the toxicity of the drug to normal tissues.

The invention provides a mycoplasma pneumoniae / chlamydia combined detection method, which efficiently enriches target genes through cascade reaction of RPA (recombinase polymerase amplification) pre-amplification (37 DEG C + / -1 DEG C, 5 minutes) and LAMP (loop-mediated isothermal amplification) targeted amplification (40 DEG C + / -2 DEG C, 15 minutes). A dUTP / UDG anti-pollution system and a closed tube operation process are adopted, an amplification product is directly mixed with a double-labeled colloidal gold probe, and double pathogens are synchronously detected through an immunochromatography test strip. The test strip is provided with two independent detection lines, FAM and digoxin reporter molecules are captured respectively, detection is completed within 25 minutes, sensitivity is high, cross contamination is avoided, and the test strip is suitable for rapid diagnosis of basic respiratory pathogens.